Yellow Carbon Dots (YC-Dots)
Yellow Carbon Dots
YC-Dots are derived from citric acid and 1,2-phenylenediamine prepared using a bottom-up approach mediated by ultrasonication. YC-Dots are highly biocompatible and have excitation-independent photoluminescence (max emission at 575 nm when excited at 400 nm). Morphology studies, including atomic force (AFM) and transmission electron microscopy (TEM), reveal that Y-CDs are spherical nanoparticles with a mean diameter of 3 nm.
Analytical spectroscopic techniques show that YC-Dots contain abundant functional groups such as carboxyl, amine, and hydroxyl groups on the surface. In addition, Y-CDs possess a high carbon content of 94%, which is rarely reported in other C-Dot species. YC-Dots have shown amphiphilicity, which allows them to cross various cell membranes and biological barriers such as the blood-brain barrier (BBB) for drug delivery.
Y-CDs have been used in research studies to enter the central nervous system (CNS) (in vivo, zebrafish model) while significantly inhibiting the expression of amyloid precursor protein (APP) and beta-amyloid (Aβ) inside cells (in vitro), which is of great significance towards the treatment of Alzheimer’s disease (AD).
Moreover, when YC-Dots were conjugated with small molecules, their amphiphilicity and capability to cross the BBB were not affected. Thus, YC-Dots have proved to be a promising versatile drug nanocarrier.
Although YC-Dots are more likely to be used in biological applications, the bright yellow photoluminescence drives the YC-Dots to use in day-to-day applications such as glow in dark parties.
Safety Information & Specifications
For the Material Safety Data Sheet for Yellow Carbon Dots, click here.
- S. Li, L. Wang, C. C. Chusuei, V. M. Suarez, P. L. Blackwelder, M. Micic, J. Orbulescu, R. M. Leblanc, Nontoxic Carbon Dots Potently Inhibit Human Insulin Fibrillation, Chem. Mater., 27 (2015) 1764-1771.
- Z. Peng, E. H Miyanji, Y. Zhou, J. Pardo, S. D Hettiarachchi, S. Li, P. L Blackwelder, I. Skromne, R. M. Leblanc, Carbon dots: Promising biomaterials for bone-specific imaging and drug delivery, Nanoscale, 9 (2017) 17533-17543.
- S. D. Hettiarachchi, R. M. Graham, K. J. Mintz, Y. Zhou, S. Vanni, Z. Peng, R. M. Leblanc, Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors, Nanoscale, 11 (2019) 6192-6205.
- Y. Zhou, P. Y. Liyanage, D. Devadoss, L. R. R. Guevara, L. Cheng, R. M. Graham, H. S. Chand, A. O. Al-Youbi, A. S. Bashammakh, M. S. El-Shahawi, R. M Leblanc, Nontoxic amphiphilic carbon dots as promising drug nanocarriers across the blood–brain barrier and inhibitors of β-amyloid, Nanoscale, 11 (2019) 22387-22397.
- Y. Zhou, K. J Mintz, L. Cheng, J. Chen, B. C. L. B Ferreira, S. D Hettiarachchi, P. Y Liyanage, E. Seven, N. Miloserdov, R. R Pandey, B. Quiroga, P. L Blackwelder, C. C Chusuei, S. Li, Z. Peng, R. M Leblanc, Direct conjugation of distinct carbon dots as lego-like building blocks for the assembly of versatile drug nanocarriers, J. Colloid Interface Sci., 576 (2020) 412-425.
- P. Y. Liyanage, R. M. Graham, R. R Pandey, C. C Chusuei, K. J. Mintz, Y. Zhou, J. K. Harper, W. Wu, A. H. Wikramanayake, S. Vanni, R. M. Leblanc, Carbon nitride dots: A selective bioimaging nanomaterial, Bioconjugate Chem., 30 (2018) 111-123.
- A. Arumov, P. Y. Liyanage, A. Trabolsi, L. Li, E. R. Roberts, D. Bilbao, R. M. LeBlanc, J. H. Schatz, Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics, Blood, 134 (2019) 4061-4063.
- P. Y. Liyanage, Y. Zhou, A. O Al-Youbi, A. S. Bashammakh, M. S. El-Shahawi, S. Vanni, R. M. Graham, R. M. Leblanc, Pediatric glioblastoma target-specific efficient delivery of gemcitabine across the blood–brain barrier via carbon nitride dots, Nanoscale, 12 (2020) 7927-7938